$VXRT
Vaxart, Inc.

2020 Q2 Form 10-Q Financial Statement

#000143774920016864 Filed on August 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2019 Q1
Revenue $523.0K $85.00K $5.407M
YoY Change 515.29% -86.02% 259.75%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.900M $1.380M $2.030M
YoY Change 182.61% -22.03% 1.0%
% of Gross Profit
Research & Development $5.114M $3.707M $3.829M
YoY Change 37.96% -26.04% 12.35%
% of Gross Profit
Depreciation & Amortization $25.00K $125.0K $130.0K
YoY Change -80.0% 3.31% 32.65%
% of Gross Profit
Operating Expenses $9.049M $5.082M $5.855M
YoY Change 78.06% -39.38% 8.07%
Operating Profit -$8.526M -$4.997M -$448.0K
YoY Change 70.62% -35.73% -88.56%
Interest Expense $97.00K $107.0K
YoY Change -28.68% -75.51%
% of Operating Profit
Other Income/Expense, Net -$425.0K -$627.0K -$641.0K
YoY Change -32.22% -42.74% -110.24%
Pretax Income -$8.951M -$5.624M -$1.089M
YoY Change 59.16% -36.6% -146.5%
Income Tax $26.00K $13.00K $250.0K
% Of Pretax Income
Net Earnings -$8.977M -$5.637M -$1.339M
YoY Change 59.25% -36.46% -157.87%
Net Earnings / Revenue -1716.44% -6631.76% -24.76%
Basic Earnings Per Share -$0.18
Diluted Earnings Per Share -$120.2K -$386.3K -$0.18
COMMON SHARES
Basic Shares Outstanding 7.301M
Diluted Shares Outstanding 7.301M

Balance Sheet

Concept 2020 Q2 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $44.40M $16.30M $8.400M
YoY Change 172.39% -31.8% -52.0%
Cash & Equivalents $44.39M $16.30M $8.400M
Short-Term Investments
Other Short-Term Assets $900.0K $800.0K $1.200M
YoY Change 12.5% -20.0% 9.09%
Inventory
Prepaid Expenses
Receivables $227.0K $35.00K $5.584M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $45.73M $17.11M $15.25M
YoY Change 167.29% -32.91% -52.19%
LONG-TERM ASSETS
Property, Plant & Equipment $345.0K $1.517M $1.559M
YoY Change -77.26% 51.7% 55.9%
Goodwill
YoY Change
Intangibles $16.23M $17.96M $18.63M
YoY Change -9.64%
Long-Term Investments
YoY Change
Other Assets $137.0K $102.0K $104.0K
YoY Change 34.31%
Total Long-Term Assets $18.46M $20.14M $21.06M
YoY Change -8.34% -9.67% -14.39%
TOTAL ASSETS
Total Short-Term Assets $45.73M $17.11M $15.25M
Total Long-Term Assets $18.46M $20.14M $21.06M
Total Assets $64.19M $37.25M $36.31M
YoY Change 72.32% -22.07% -35.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.166M $610.0K $849.0K
YoY Change 91.15% -56.43% -50.06%
Accrued Expenses $6.378M $1.485M $1.727M
YoY Change 329.49% -35.43% -17.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due $3.200M $1.700M $1.700M
YoY Change 88.24% 0.0% 0.0%
Total Short-Term Liabilities $11.50M $7.477M $8.550M
YoY Change 53.78% -15.03% 9.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.200M $1.600M
YoY Change -100.0% -55.56% -48.39%
Other Long-Term Liabilities $18.00K $18.00K $18.00K
YoY Change 0.0% -99.87% -99.88%
Total Long-Term Liabilities $18.00K $18.00K $18.00K
YoY Change 0.0% -99.89% -99.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.50M $7.477M $8.550M
Total Long-Term Liabilities $18.00K $18.00K $18.00K
Total Liabilities $23.96M $21.41M $23.73M
YoY Change 11.91% -15.73% -6.56%
SHAREHOLDERS EQUITY
Retained Earnings -$126.9M -$105.0M -$99.36M
YoY Change 20.9%
Common Stock $167.2M $120.8M $111.9M
YoY Change 38.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $40.24M $15.85M $12.58M
YoY Change
Total Liabilities & Shareholders Equity $64.19M $37.25M $36.31M
YoY Change 72.32% -22.07% -35.74%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income -$8.977M -$5.637M -$1.339M
YoY Change 59.25% -36.46% -157.87%
Depreciation, Depletion And Amortization $25.00K $125.0K $130.0K
YoY Change -80.0% 3.31% 32.65%
Cash From Operating Activities -$520.0K -$320.0K -$4.653M
YoY Change 62.5% -104.51% -56.06%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$160.0K $552.0K
YoY Change -93.75% -20.0% 294.29%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$10.00K -$160.0K -$552.0K
YoY Change -93.75% -20.0% -102.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.300M $2.500M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.06M 8.310M 2.123M
YoY Change 81.23% -1868.09% -901.13%
NET CHANGE
Cash From Operating Activities -520.0K -320.0K -4.653M
Cash From Investing Activities -10.00K -160.0K -552.0K
Cash From Financing Activities 15.06M 8.310M 2.123M
Net Change In Cash 14.53M 7.830M -3.082M
YoY Change 85.57% 21.77% -119.35%
FREE CASH FLOW
Cash From Operating Activities -$520.0K -$320.0K -$4.653M
Capital Expenditures -$10.00K -$160.0K $552.0K
Free Cash Flow -$510.0K -$160.0K -$5.205M
YoY Change 218.75% -102.19% -51.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0000072444
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
129608000
CY2020Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10355914
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
45476994
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
dei Trading Symbol
TradingSymbol
vxrt
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1166000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
852000
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
227000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3619000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6378000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4565000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
49000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
503000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
459000
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
167160000
dei Entity Registrant Name
EntityRegistrantName
Vaxart, Inc.
dei Entity Small Business
EntitySmallBusiness
true
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2860000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2956000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
180000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
344000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
560000
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
433000
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
675000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
866000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1454000
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26588035
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13363762
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31169834
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7157602
CY2020Q2 us-gaap Assets
Assets
64190000
CY2019Q4 us-gaap Assets
Assets
37032000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
45726000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
17598000
CY2020Q2 us-gaap Cash
Cash
44388000
CY2019Q4 us-gaap Cash
Cash
13511000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44388000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13526000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11506000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16258000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
30862000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4752000
CY2020Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1942654
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
96140661
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48254994
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
96140661
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48254994
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
10000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
5000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Concentration of Credit Risk</div>&nbsp;&#x2013;&nbsp;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and accounts receivable. The Company places its cash and&nbsp;cash equivalents at financial institutions that management believes are of high credit quality. The Company is exposed to credit risk in the event of default by the financial institutions holding the cash and cash equivalents to the extent such amounts are in excess of the federally insured limits. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any losses on its deposits since inception.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The primary focus of the Company's investment strategy is to preserve capital and meet liquidity requirements. The Company's investment policy addresses the level of credit exposure by limiting the concentration in any <div style="display: inline; font-style: italic; font: inherit;">one</div>&nbsp;corporate issuer or sector and establishing a minimum allowable credit rating. The Company generally requires <div style="display: inline; font-style: italic; font: inherit;">no</div> collateral from its customers.</div></div></div>
CY2020Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
181000
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2020Q2 us-gaap Depreciation
Depreciation
25000
CY2019Q2 us-gaap Depreciation
Depreciation
125000
us-gaap Depreciation
Depreciation
44000
us-gaap Depreciation
Depreciation
255000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1193000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2097000
us-gaap Dilutive Securities
DilutiveSecurities
0
us-gaap Dilutive Securities
DilutiveSecurities
0
CY2020Q2 us-gaap Dilutive Securities
DilutiveSecurities
0
CY2019Q2 us-gaap Dilutive Securities
DilutiveSecurities
0
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1009000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
903000
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5900000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5087000
CY2020Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5953000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1732000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
866000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1732000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1732000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1731000
CY2020Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
22180000
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
22180000
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
16227000
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2000
CY2019Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-48000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-43000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3896000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1375000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5886000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3401000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-8951000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5624000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10095000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-6713000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
179000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
263000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
148000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-347000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3392000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1761000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1376000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-371000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
657000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-530000
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
16227000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
17093000
CY2020Q2 us-gaap Interest Expense
InterestExpense
CY2019Q2 us-gaap Interest Expense
InterestExpense
97000
us-gaap Interest Expense
InterestExpense
us-gaap Interest Expense
InterestExpense
204000
CY2020Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
23000
CY2019Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
34000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2312000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
64000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
39000
us-gaap Interest Paid Net
InterestPaidNet
us-gaap Interest Paid Net
InterestPaidNet
136000
CY2020Q2 us-gaap Lease Cost
LeaseCost
173000
CY2019Q2 us-gaap Lease Cost
LeaseCost
211000
us-gaap Lease Cost
LeaseCost
322000
us-gaap Lease Cost
LeaseCost
431000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
620000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
360000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
348000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
336000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
526000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
388000
CY2020Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020Q2 us-gaap Liabilities
Liabilities
23955000
CY2019Q4 us-gaap Liabilities
Liabilities
24080000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64190000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37032000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11498000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9174000
CY2020Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
CY2019Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
15000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34601000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10433000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-711000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3729000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4970000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8977000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-5637000
us-gaap Net Income Loss
NetIncomeLoss
-10274000
us-gaap Net Income Loss
NetIncomeLoss
-6976000
us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
170000
us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
47000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-425000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-627000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-875000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1268000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
9049000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
5082000
us-gaap Operating Expenses
OperatingExpenses
12645000
us-gaap Operating Expenses
OperatingExpenses
10937000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8526000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4997000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9220000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5445000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
212000
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
222000
us-gaap Operating Lease Cost
OperatingLeaseCost
401000
us-gaap Operating Lease Cost
OperatingLeaseCost
445000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1924000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
804000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
841000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1120000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1472000
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
237000
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
240000
us-gaap Operating Lease Payments
OperatingLeasePayments
474000
us-gaap Operating Lease Payments
OperatingLeasePayments
487000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1755000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1990000
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1053
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y200D
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
383000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
254000
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
137000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
141000
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18000
us-gaap Other Noncash Expense
OtherNoncashExpense
us-gaap Other Noncash Expense
OtherNoncashExpense
64000
us-gaap Payments For Restructuring
PaymentsForRestructuring
518000
CY2020Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
775000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
711000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.10
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1111000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
453000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;">Reclassification</div> &#x2013; Prior periods' data is subject to reclassification to conform to the current presentation. Accordingly,&nbsp;<div style="display: inline; font-style: italic; font: inherit;">$40,000</div> and <div style="display: inline; font-style: italic; font: inherit;">$88,000</div> that were previously recorded as non-lease costs have&nbsp;been included as variable lease costs and in cash outflows related to leases in the <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">six</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2019, </div>respectively.&nbsp;This&nbsp;reclassification&nbsp;had <div style="display: inline; font-style: italic; font: inherit;">no</div> effect on reported net loss.</div></div></div>
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9175000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2540000
CY2020Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
10000000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
116000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
24658000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
848000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
669000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
345000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
210000
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
833000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5114000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3707000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6656000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7536000
CY2020Q2 us-gaap Restructuring And Related Cost Cost Incurred To Date1
RestructuringAndRelatedCostCostIncurredToDate1
5023000
CY2020Q2 us-gaap Restructuring Charges
RestructuringCharges
39000
CY2019Q2 us-gaap Restructuring Charges
RestructuringCharges
us-gaap Restructuring Charges
RestructuringCharges
103000
us-gaap Restructuring Charges
RestructuringCharges
CY2019Q4 us-gaap Restructuring Reserve
RestructuringReserve
3648000
CY2020Q2 us-gaap Restructuring Reserve
RestructuringReserve
3233000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126935000
CY2020Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
3000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116661000
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
523000
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
85000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3425000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5492000
CY2020Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
20000
CY2019Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
211000
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P90D
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
1
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
8800000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1431750
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.22
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.65
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
10.50
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.39
CY2020Q2 us-gaap Short Term Lease Commitment Amount
ShortTermLeaseCommitmentAmount
0
us-gaap Share Based Compensation
ShareBasedCompensation
2956000
us-gaap Share Based Compensation
ShareBasedCompensation
344000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
6400000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
295180
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1620028
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
524000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
57147
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
85992
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
4892100
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2610000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
43100000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6382232
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1811652
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.22
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.74
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.70
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.04
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y135D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y113D
CY2019Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
6000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
7000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
178381
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2440000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
98000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
116000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
40235000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
12952000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
31293000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
12576000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
15845000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
11238000
CY2020Q2 us-gaap Sublease Income
SubleaseIncome
55000
CY2019Q2 us-gaap Sublease Income
SubleaseIncome
55000
us-gaap Sublease Income
SubleaseIncome
109000
us-gaap Sublease Income
SubleaseIncome
109000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Use of Estimates</div>&nbsp;&#x2013;&nbsp;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Actual results and outcomes could differ from these estimates and assumptions.</div></div></div>
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
13000
CY2019Q2 us-gaap Variable Lease Cost
VariableLeaseCost
40000
us-gaap Variable Lease Cost
VariableLeaseCost
24000
us-gaap Variable Lease Cost
VariableLeaseCost
88000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
74675131
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14597446
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67676138
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10969473
CY2020Q2 vxrt Accrued Clinical And Manufacturing Expenses Current
AccruedClinicalAndManufacturingExpensesCurrent
4937000
CY2019Q4 vxrt Accrued Clinical And Manufacturing Expenses Current
AccruedClinicalAndManufacturingExpensesCurrent
3228000
CY2020Q2 vxrt Adjustments To Additional Paid In Capital Disgorgement Of Shortswing Profits Net Of Costs
AdjustmentsToAdditionalPaidInCapitalDisgorgementOfShortswingProfitsNetOfCosts
652000
vxrt Adjustments To Additional Paid In Capital Disgorgement Of Shortswing Profits Net Of Costs
AdjustmentsToAdditionalPaidInCapitalDisgorgementOfShortswingProfitsNetOfCosts
652000
vxrt Adjustments To Additional Paid In Capital Stock And Warrants Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts
1278000
CY2019Q2 vxrt Adjustments To Additional Paid In Capital Stock And Warrants Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts
1579000
vxrt Adjustments To Additional Paid In Capital Stock And Warrants Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts
1579000
CY2018Q1 vxrt Business Combination Stock Conversion Shares Issued Per Common Share Of Surviving Entity
BusinessCombinationStockConversionSharesIssuedPerCommonShareOfSurvivingEntity
0.22148
CY2020Q2 vxrt Contract With Customer Asset Revenue Recognized
ContractWithCustomerAssetRevenueRecognized
212000
CY2019Q4 vxrt Contract With Customer Asset Revenue Recognized
ContractWithCustomerAssetRevenueRecognized
21000
CY2020Q2 vxrt Finitelived Intangible Asset Expected Amortization Year Five And Thereafter
FinitelivedIntangibleAssetExpectedAmortizationYearFiveAndThereafter
8434000
vxrt Impairment Of Property And Equipment
ImpairmentOfPropertyAndEquipment
0
vxrt Impairment Of Property And Equipment
ImpairmentOfPropertyAndEquipment
0
vxrt Issuance Of Warrants To Placement Agents Designees
IssuanceOfWarrantsToPlacementAgentsDesignees
453000
vxrt Issuance Of Warrants To Placement Agents Designees
IssuanceOfWarrantsToPlacementAgentsDesignees
100000
vxrt Issuance Of Warrants To Underwriters Designees
IssuanceOfWarrantsToUnderwritersDesignees
vxrt Issuance Of Warrants To Underwriters Designees
IssuanceOfWarrantsToUnderwritersDesignees
333000
CY2020Q2 vxrt Lessee Finance Lease Number Of Leases
LesseeFinanceLeaseNumberOfLeases
0
CY2020Q2 vxrt Lessee Operating Lease Liability To Be Paid Year Five And Thereafter
LesseeOperatingLeaseLiabilityToBePaidYearFiveAndThereafter
122000
CY2020Q2 vxrt Lessee Operating Lease Number Leases Exceeding One Year
LesseeOperatingLeaseNumberLeasesExceedingOneYear
3
CY2020Q2 vxrt Lessee Operating Lease Number Of Leases
LesseeOperatingLeaseNumberOfLeases
4
CY2020Q2 vxrt Lessee Operating Lease Number Of Right Of Use Leases Terminated
LesseeOperatingLeaseNumberOfRightOfUseLeasesTerminated
1
CY2020Q2 vxrt Lessee Operating Lease Number Of Rightofuse Leases Subleased
LesseeOperatingLeaseNumberOfRightofuseLeasesSubleased
1
CY2020Q2 vxrt Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
3150000
CY2019Q4 vxrt Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
2916000
CY2020Q2 vxrt Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
11319000
CY2019Q4 vxrt Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
13416000
vxrt Net Proceeds From Issuance Of Common Stock Pre Funded Warrants And Common Warrants In Underwritten Offering
NetProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrantsInUnderwrittenOffering
vxrt Net Proceeds From Issuance Of Common Stock Pre Funded Warrants And Common Warrants In Underwritten Offering
NetProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndCommonWarrantsInUnderwrittenOffering
8074000
CY2020Q2 vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
446000
CY2019Q2 vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
516000
vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
937000
vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
1060000
vxrt Noncash Revenue Related To Sale Of Future Royalties
NoncashRevenueRelatedToSaleOfFutureRoyalties
2800000
vxrt Noncash Revenue Related To Sale Of Future Royalties
NoncashRevenueRelatedToSaleOfFutureRoyalties
3132000
vxrt Proceeds From Disgorgement Of Shortswing Profits Net Of Costs
ProceedsFromDisgorgementOfShortswingProfitsNetOfCosts
652000
vxrt Proceeds From Disgorgement Of Shortswing Profits Net Of Costs
ProceedsFromDisgorgementOfShortswingProfitsNetOfCosts
vxrt Proceeds From Exercise Of Prefunded Warrants
ProceedsFromExerciseOfPrefundedWarrants
vxrt Proceeds From Exercise Of Prefunded Warrants
ProceedsFromExerciseOfPrefundedWarrants
652000
CY2020Q1 vxrt Proceeds From Issuance Or Sale Of Equity Net
ProceedsFromIssuanceOrSaleOfEquityNet
9200000
CY2020Q2 vxrt Reserve For Return Of Royalties Current
ReserveForReturnOfRoyaltiesCurrent
CY2019Q4 vxrt Reserve For Return Of Royalties Current
ReserveForReturnOfRoyaltiesCurrent
178000
vxrt Share Based Compensation Arrangement By Share Based Payment Award Canceled
ShareBasedCompensationArrangementByShareBasedPaymentAwardCanceled
9573
vxrt Share Based Compensation Arrangement By Share Based Payment Award Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeited
85910
vxrt Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Decrease From Grants
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantDecreaseFromGrants
-4892100
vxrt Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
8722000
CY2019Q2 vxrt Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
7741000
vxrt Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
7741000
CY2020Q2 vxrt Stock Issued During Period Value Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
14309000
vxrt Stock Issued During Period Value Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
24658000
CY2019Q2 vxrt Stock Issued During Period Value Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
652000
vxrt Stock Issued During Period Value Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
652000

Files In Submission

Name View Source Status
0001437749-20-016864-index-headers.html Edgar Link pending
0001437749-20-016864-index.html Edgar Link pending
0001437749-20-016864.txt Edgar Link pending
0001437749-20-016864-xbrl.zip Edgar Link pending
ex_194467.htm Edgar Link pending
ex_194468.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pipeline20q1b.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vxrt-20200630.xml Edgar Link completed
vxrt-20200630.xsd Edgar Link pending
vxrt-20200630_cal.xml Edgar Link unprocessable
vxrt-20200630_def.xml Edgar Link unprocessable
vxrt-20200630_lab.xml Edgar Link unprocessable
vxrt-20200630_pre.xml Edgar Link unprocessable
vxrt20200630b_10q.htm Edgar Link pending